503Pharma Weekly Compounding Pharmacy Roundup

JOIN FREE MEMBERS AREA | COMPLIANCE TRAINING | FORMULA LIBRARY

This Week's Headlines

Regulatory

FDA Moves to Permanently Block 503B GLP-1 Compounding

FDA published a Federal Register notice on May 1 proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The agency was explicit: backorders, convenience, and lower cost are not "clinical need." Comments due June 29. If finalized, large-scale 503B GLP-1 compounding closes — even if a future shortage is declared.

FDA → Press Announcement

Industry

APC Pushes Back on FDA's Bulks Proposal

The Alliance for Pharmacy Compounding said the proposal "does not change the status quo" — 503B GLP-1 compounding has primarily occurred during shortages anyway. APC is reviewing the rule and signaling it will press FDA on the narrow read of clinical need during the comment window. Watch the formal filing for the industry's litigation posture.

APC → Statement on FDA Proposed Rule

Inspections

FDA Launches AI-Screened One-Day Inspection Pilot

FDA announced that it has been piloting one-day inspectional assessments across drug, biologics, and food inspectorates since April, using AI to flag low-risk facilities for shorter targeted screenings. About 46 assessments have been completed so far; most resulted in No Action Indicated outcomes, but investigators retained authority to extend any assessment that surfaced issues. Compounding pharmacies — particularly 503Bs — should expect more frequent, AI-targeted FDA encounters with shorter notice and tighter scope, while standard for-cause inspections continue unchanged.

FDA → Press Announcement (May 6, 2026)

Market

Ro Signs Brand Deal With Lilly for Orforglipron

Ro will prescribe Lilly's oral GLP-1 Foundayo (orforglipron) alongside semaglutide and tirzepatide. Follows the March Hims–Novo Nordisk pact. Two of the largest direct-to-consumer telehealth platforms are now selling brand as their primary GLP-1 channel. The compounded GLP-1 referral pipeline from major telehealth is narrowing fast.

Press Release

Peptides

FDA Sets July 23–24 PCAC on BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epitalon

The Pharmacy Compounding Advisory Committee will review seven peptide bulk substances for 503A Bulks List inclusion. A second meeting is planned before end of February 2027. Public docket FDA-2026-N-2979 is open through July 22. FDA also formally renewed the PCAC charter on April 30, locking the committee in for both review windows.

FDA → PCAC Meeting Notice

Research Desk

Peptide Evidence

What's in Clinical Trials

MOTS-c (NCT07505745): Hudson Biotech is recruiting for a Phase 2a randomized, double-blind, placebo-controlled study of subcutaneous MOTS-c in adults with prediabetes and overweight/obesity, evaluating efficacy, safety, and pharmacodynamics. Investigational only — pharmacies should avoid claiming MOTS-c treats insulin resistance, obesity, or mitochondrial dysfunction.

BPC-157 (NCT07437547): A newly recruiting Phase 2 trial is evaluating pentadecapeptide BPC-157 for accelerated repair of MRI-confirmed acute Grade II hamstring strain. An earlier Phase 1 study in healthy volunteers (NCT02637284) covered safety and PK of an oral BPC-157 product. That's the human evidence base — not validation of the broad tendon-repair, gut-healing, or "regeneration" claims circulating online.

TB-500 / Thymosin Beta-4 (NCT07487363): Hudson Biotech is recruiting for a Phase 1/2 study of TB-500 (thymosin beta 4 17-23 fragment) in adults with stable atherosclerotic cardiovascular disease, evaluating safety, tolerability, PK, and exploratory cardiovascular biomarkers. Note this is a fragment study in a cardiovascular indication — not the wound-healing or ocular-surface contexts where most of the existing thymosin beta-4 literature sits. Route, formulation, dose, and indication all matter when claims are made.

GLP-1 lean-mass preservation (NCT07091500): Washington University School of Medicine is recruiting for a study evaluating the effect of GLP-1 receptor agonist therapy with and without exercise training on muscle mass and physical function in people with obesity. A separate Pennington Biomedical study (NCT07154719) is examining tirzepatide effects on muscle and skeletal outcomes. Both are directly relevant to combination GLP-1 products marketed around fatigue, muscle loss, or "lean-mass support." "Supports patients during therapy" is a very different claim than "prevents muscle loss."

Injectable NAD+ vs. NR head-to-head (NCT06919328): Nutraceuticals Research Institute is running a double-blind RCT comparing injectable nicotinamide riboside (Niagen) to injectable NAD+ for absorption and tolerability (70 participants). First registered head-to-head trial on the injectable route that many compounding pharmacies already compound — could establish route-specific PK data for a high-margin formulation category.

ClinicalTrials.gov → Active Peptide & GLP-1 Studies

503Pharma Formula Library

90+ ready-to-use formulations for sterile and non-sterile compounding, built to USP 795/797 with BUD assignments included. Updated as guidance changes.

Access the Formula Library →

CompoundLearn — USP Training for Your Whole Team

Role-based USP 795/797/800 training with quizzes, certificates, and inspection-ready documentation. Built for onboarding, annual training, and pharmacy-wide compliance readiness.

Start Training Your Team →

✉️ That's your 503Pharma weekly digest. Our mission is to keep compounding professionals informed, prepared, and ahead of the curve.